Instrument Inactif

Communiqués Cornerstone Therapeutics, Inc.

Actions

US21924P1030

Produits pharmaceutiques

Cours en clôture Nasdaq Autres places de cotation
- ^USD	-

16/09/13	USA-Les valeurs à suivre à Wall Street (actualisé)	RE
16/09/13	USA-Les valeurs à suivre à Wall Street (actualisé)	RE

Communiqués

28/02/14	Cornerstone Therapeutics, Inc. : Cornerstone Therapeutics Inc. Stockholders Approve Merger	PU
03/02/14	Cornerstone Therapeutics Inc. Stockholders Approve Merger	MW
01/02/14	Cornerstone Therapeutics Adjourns Special Meeting of Stockholders	MW
20/11/13	Cornerstone Therapeutics, Inc. : Cornerstone Therapeutics Launches BETHKIS(R) (Tobramycin Inhalation Solution) for Management of Cystic Fibrosis Patients With Pseudomonas Aeruginosa	PU
31/10/13	Cornerstone Therapeutics, Inc. : Cornerstone Therapeutics to Host Third Quarter 2013 Conference Call	PU
24/09/13	Cornerstone Therapeutics, Inc. : Law Firm Brower Piven Announces Class Action Lawsuit in Connection With Claims of Breaches of Fiduciary Duty by the Board of Cornerstone Therapeutics, Inc. in Connection With a Proposed Buyout	BU
19/09/13	Cornerstone Therapeutics, Inc. : SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Cornerstone Therapeutics, Inc. Buyout	BU
19/09/13	Cornerstone Therapeutics, Inc. : SHAREHOLDER ALERT: Law Office of Brodsky & Smith, LLC Announces Investigation of Cornerstone Therapeutics, Inc.	BU
17/09/13	Cornerstone Therapeutics, Inc. : SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by Board of Cornerstone Therapeutics, Inc. in Connection with Sale of Company to Chiesi Farmaceutici S.p.A.	BU
16/09/13	Cornerstone Therapeutics, Inc. : Rigrodsky & Long, P.A. Announces Investigation Of Cornerstone Therapeutics, Inc. Buyout	BU
16/09/13	Cornerstone Therapeutics, Inc. : Shareholder Rights Law Firm Johnson & Weaver, LLP, is Investigating the Cornerstone Buyout	BU
16/09/13	Cornerstone Therapeutics, Inc. : Cornerstone Therapeutics Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Acquisition by Chiesi Farmaceutici	BU
16/09/13	Cornerstone Therapeutics, Inc. : Law Firm Brower Piven Announces Investigation of Cornerstone Therapeutics, Inc. Proposed Acquisition	BU
16/09/13	Cornerstone Therapeutics, Inc. : Finkelstein Thompson LLP Announces Investigation of Cornerstone Therapeutics Inc. Buyout	BU
16/09/13	Cornerstone Therapeutics, Inc. : Chiesi Farmaceutici and Cornerstone Therapeutics Announce Agreement for a Merger Transaction in Which Chiesi Will Acquire 100 Percent Ownership of Cornerstone for $9.50 per Share in Cash	PU
04/09/13	Cornerstone Therapeutics, Inc. : Cornerstone Therapeutics Reports First Quarter 2013 Financial Results	PU
03/08/13	Cornerstone Therapeutics, Inc. : REMINDER: Cornerstone Therapeutics to Host First Quarter 2013 Conference Call	PU
25/07/13	Cornerstone Therapeutics, Inc. : Cornerstone Therapeutics Sues to Enforce Its CARDENE(R) I.V. Patents	PU
01/07/13	Cornerstone Therapeutics, Inc. : Cornerstone Therapeutics to Host Fourth Quarter and Full Year 2012 Conference Call	PU
13/06/13	Cornerstone Therapeutics, Inc. : Cornerstone Therapeutics Receives CARDENE(R) I.V. (Nicardipine Hydrochloride) Paragraph IV Notice Letter	PU
26/02/13	Cornerstone Therapeutics, Inc. : SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches Investigation in Possible Breaches of Fiduciary Duty by the Board of Cornerstone Therapeutics, Inc. in Connection with a Going Private Proposal	BU
25/02/13	Cornerstone Therapeutics, Inc. : Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of Cornerstone Therapeutics Inc. Shareholders	BU
22/02/13	Cornerstone Therapeutics, Inc. : Cornerstone Therapeutics Shareholder Alert: Briscoe Law Firm and Powers Taylor, LLP Investigate Going Private Proposal	BU
15/05/12	Cornerstone Therapeutics, Inc. : Cornerstone Therapeutics to Acquire EKR Therapeutics, Accelerating Expansion in Hospital Market	PU
13/03/12	Cornerstone Therapeutics, Inc. : Cornerstone Therapeutics Receives FDA Acceptance for CRTX 080 NDA for Treatment of Hyponatremia	PU